This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

MarketWatch· Jaimy Lee· Sep 22, 2026 · 3:46 PM

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.

This is a summary. Read the complete story at MarketWatch below.

Read full article at MarketWatch

Elon Musk opens the door for a big SpaceX acquisition

The rocket and satellite-internet company is looking to challenge telecom giants.

MarketWatch

marketsabout 10 hours ago

Data centers run on debt. That was a problem for bonds this year — and it’s only going to get worse.

AI debt issuance this year overwhelmed investor portfolios, and has disappointed from a performance perspective. The funding need won’t get any better with Democrats in control of Congress.

MarketWatch

marketsabout 10 hours ago

Micron’s stock is dirt cheap — and that’s igniting a fierce online debate

Valuation purists see a ridiculously inexpensive stock, but some semiconductor investors say Micron’s earnings power won’t hold up.

MarketWatch

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Related Stories

Elon Musk opens the door for a big SpaceX acquisition

Data centers run on debt. That was a problem for bonds this year — and it’s only going to get worse.

Micron’s stock is dirt cheap — and that’s igniting a fierce online debate